News
FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t
